Rebecca A. Marsh, MD
- Clinical Director, Primary Immune Deficiency Program
- Co-Director, Diagnostic Immunology Laboratories
- Clinical Director, HLH Center of Excellence
- Professor, UC Department of Pediatrics
- hlh@cchmc.org
- Board Certified
About
Biography
I’ve always been fascinated by the immune system and also felt a calling to pediatrics. I enjoy working with people and developing long-term relationships with patients and families, so my career in primary immune deficiencies and hematopoietic cell transplantation is a perfect fit. My practice combines my love of immunology with caring for pediatric patients and working in a team-based setting.
As an immunologist and transplant physician, I treat patients with primary immune deficiencies and immune regulatory diseases, which are collectively called inborn errors of immunity. I’m the clinical director of the Primary Immune Deficiency Program and co-director of Diagnostic Immunology Laboratory.
Our practice provides a variety of treatments for patients, including allogeneic hematopoietic cell transplantation. Each patient and family is different, and I enjoy getting to know each person and helping them live their best life through optimal treatment of their immune deficiency.
We have a large group of specialists in the diagnosis and treatment of inborn errors of immunity. We also have the largest clinical laboratory specializing in primary immunodeficiency diagnostics. Our physician group consists of several experts in primary immunodeficiencies. Our physicians not only provide state-of-the-art treatment for patients, but they also lead the field with primary immune deficiency research and new treatment trials.
We have many nurse practitioners dedicated to caring for patients with inborn errors of immunity. Patients in our practice also work with a dedicated nurse coordinator who helps patients navigate their medical care. Our practice is special because we provide cutting-edge diagnostics and treatments for our patients and also maintain a supportive and caring team-based environment.
Through my research, I want to improve allogeneic hematopoietic cell transplantation for patients with primary immunodeficiencies. I’m also working to improve the treatment of patients with X-linked inhibitor of apoptosis (XIAP) deficiency and hemophagocytic lymphohistiocytosis (HLH).
In my free time, I like to play the piano, bake and spend time with my family.
BS: University of Tennessee, Knoxville, TN, 1998.
MD: Rush Medical College, Chicago, IL, 2003.
Residency: Rush University Medical Center, Chicago, IL, 2006.
Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2008.
Services and Specialties
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism. Blood. 2024; 144:2625-2636.
High symptom burden in female X-linked chronic granulomatous disease carriers. Clinical Immunology. 2024; 268:110364.
COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report. Journal of Clinical Immunology. 2024; 44:86.
Ruxolitinib Pharmacokinetics and Pharmacodynamics in Children with Acute and Chronic Graft-versus-Host Disease. Transplantation and Cellular Therapy. 2024; 30:528.e1-528.e12.
Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: A Primary Immune Deficiency Treatment Consortium study. Journal of Allergy and Clinical Immunology. 2024; 153:1423-1431.e2.
Relevance of lymphocyte proliferation to PHA in severe combined immunodeficiency (SCID) and T cell lymphopenia. Clinical Immunology. 2024; 261:109942.
Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputation. Blood. 2024; 143:872-881.
Emapalumab Therapy Prior to Hematopoietic Stem Cell Transplant Is Associated with Improved Long-Term Chimerism and Event-Free Survival in Pediatric Patients with Hemophagocytic Lymphohistiocytosis. Transplantation and Cellular Therapy. 2024; 30:s93.
Outcomes Following Matched Sibling Donor Transplant for Severe Combined Immunodeficiency: A Report from the Pidtc. Transplantation and Cellular Therapy. 2024; 30:s92-s93.
Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. Pediatric Rheumatology Online Journal. 2024; 21:86.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey